Ejso最新文献

英文中文

IFC: Filler advert_sciencedirect_210x280.pdf

IF 3.5 2区医学 Q2 ONCOLOGY

Ejso

Pub Date : 2024-09-17 DOI: 10.1016/S0748-7983(24)00730-3

引用次数: 0

Filler advert_scopus_2021_210x280.pdf

IF 3.5 2区医学 Q2 ONCOLOGY

Ejso

Pub Date : 2024-09-17 DOI: 10.1016/S0748-7983(24)00733-9

引用次数: 0

Filler advert_pharmapendium_2021_210x280.pdf

IF 3.5 2区医学 Q2 ONCOLOGY

Ejso

Pub Date : 2024-09-17 DOI: 10.1016/S0748-7983(24)00731-5

引用次数: 0

Effect of postoperative normothermic intraperitoneal chemotherapy on the prognosis of MPM patients receiving CRS+HIPEC: A single-center case-control study

IF 3.5 2区医学 Q2 ONCOLOGY

Ejso

Pub Date : 2024-09-14 DOI: 10.1016/j.ejso.2024.108692

Background

The comprehensive treatment strategy, mainly cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC), combined with systemic and intraperitoneal chemotherapy, is the standard treatment for malignant peritoneal mesothelioma (MPM), which can significantly prolong the survival of patients. The aim of this study is to investigate the clinical significance of postoperative normothermic intraperitoneal chemotherapy (NIPEC) in MPM patients.

Methods

Data of 152 MPM patients who underwent CRS + HIPEC and postoperative intravenous chemotherapy were retrospectively analyzed. Patients were divided into the Non-NIPEC group and the NIPEC group according to whether they received NIPEC after surgery. The baseline characteristics of the two groups were compared, and the survival outcome was analyzed in subgroups according to completeness of cytoreduction (CC) score. Multivariate survival analysis was used to determine the independent prognostic factors.

Results

In CC 0–1 and CC 2–3 subgroups, there was no significant difference in baseline characteristics between Non-NIPEC and NIPEC groups. Survival analysis showed that for CC 0–1 patients, there was no significant difference in overall survival (OS) between Non-NIPEC and NIPEC groups (P = 0.503). However, for CC 2–3 patients, the median OS of the NIPEC group was significantly longer than that of the Non-NIPEC group (24.5 vs. 10.3 months, P = 0.005). Pathological type, preoperative thrombosis and postoperative NIPEC (HR = 0.423, 95%CI: 0.228–0.786, P = 0.006) were independent prognostic factors for CC 2–3 patients.

Conclusions

For MPM patients receiving CRS + HIPEC, postoperative intraperitoneal combined with intravenous chemotherapy may improve the survival of CC 2–3 patients, but CC 0–1 patients do not seem to derive the same benefit.

{"title":"Effect of postoperative normothermic intraperitoneal chemotherapy on the prognosis of MPM patients receiving CRS+HIPEC: A single-center case-control study","authors":"","doi":"10.1016/j.ejso.2024.108692","DOIUrl":"10.1016/j.ejso.2024.108692","url":null,"abstract":"<div><h3>Background</h3><p>The comprehensive treatment strategy, mainly cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC), combined with systemic and intraperitoneal chemotherapy, is the standard treatment for malignant peritoneal mesothelioma (MPM), which can significantly prolong the survival of patients. The aim of this study is to investigate the clinical significance of postoperative normothermic intraperitoneal chemotherapy (NIPEC) in MPM patients.</p></div><div><h3>Methods</h3><p>Data of 152 MPM patients who underwent CRS + HIPEC and postoperative intravenous chemotherapy were retrospectively analyzed. Patients were divided into the Non-NIPEC group and the NIPEC group according to whether they received NIPEC after surgery. The baseline characteristics of the two groups were compared, and the survival outcome was analyzed in subgroups according to completeness of cytoreduction (CC) score. Multivariate survival analysis was used to determine the independent prognostic factors.</p></div><div><h3>Results</h3><p>In CC 0–1 and CC 2–3 subgroups, there was no significant difference in baseline characteristics between Non-NIPEC and NIPEC groups. Survival analysis showed that for CC 0–1 patients, there was no significant difference in overall survival (OS) between Non-NIPEC and NIPEC groups (<em>P</em> = 0.503). However, for CC 2–3 patients, the median OS of the NIPEC group was significantly longer than that of the Non-NIPEC group (24.5 <em>vs.</em> 10.3 months, <em>P</em> = 0.005). Pathological type, preoperative thrombosis and postoperative NIPEC (HR = 0.423, 95%CI: 0.228–0.786, <em>P</em> = 0.006) were independent prognostic factors for CC 2–3 patients.</p></div><div><h3>Conclusions</h3><p>For MPM patients receiving CRS + HIPEC, postoperative intraperitoneal combined with intravenous chemotherapy may improve the survival of CC 2–3 patients, but CC 0–1 patients do not seem to derive the same benefit.</p></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142239154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter to the editor: Transforming cancer care: The vital role of prehabilitation in colorectal surgery

IF 3.5 2区医学 Q2 ONCOLOGY

Ejso

Pub Date : 2024-09-14 DOI: 10.1016/j.ejso.2024.108694

引用次数: 0

Preoperative geriatric assessment to predict functional outcome after major urologic operations: Results from a multicenter study

IF 3.5 2区医学 Q2 ONCOLOGY

Ejso

Pub Date : 2024-09-14 DOI: 10.1016/j.ejso.2024.108693

Introduction

Major urological tumor surgery entails a severe risk of unexpected adverse events, persistent functional deterioration, and death in older patients. The Erlangen Index (EI) geriatric assessment tool has previously been shown to predict incomplete functional recovery following major urological tumor surgery in an elderly patient collective. We prospectively evaluated assessment tools including EI in a multicenter setting.

Materials and methods

A total of 340 patients over the age of 65 were assessed prospectively before and after cystectomy, prostatectomy, or renal tumor surgery at three academic centers in Germany and Austria. Endpoints were long-term functional deterioration (Activities of daily living (ADL) measured by Barthel-Index) at day 30 and day 180, and mortality at day 180.

Results

In this study 58 (17.0 %) patients underwent cystectomy, 140 (41.2 %) prostatectomy and 142 (41.8 %) a kidney tumor operation. Mean age was 74.8 years. ADL impairment as a measure of incomplete recovery at day 30 and 180 after surgery were recorded in 47.6 % and 37.4 % of cases, respectively. The EI showed good sensitivity for mortality at day 180 (reference cohort: 85 %, validation center 1: 100 %, validation center 2: 50 %) and for ADL impairment at day 180 (reference cohort 75.4 %, validation center 1 72.3 %, validation center 2 83.3 %).

Conclusion

Elderly patients with a poor performance status have a high risk of persistent functional deterioration. Data from this multicenter external validation trial confirms the EI as an accurate and reliable tool to identify patients with high risk of mortality or persistent postoperative functional impairment.

导言：泌尿系统肿瘤大手术对于老年患者来说，存在发生意外不良事件、功能持续恶化和死亡的严重风险。埃尔朗根指数（EI）老年评估工具曾被证明可以预测老年患者在泌尿系统肿瘤大手术后功能恢复不完全的情况。我们在多中心环境中对包括 EI 在内的评估工具进行了前瞻性评估。材料和方法在德国和奥地利的三个学术中心对 340 名 65 岁以上的患者进行了膀胱切除术、前列腺切除术或肾肿瘤手术前后的前瞻性评估。终点是第 30 天和第 180 天的长期功能衰退（日常生活活动能力（ADL）以 Barthel 指数衡量）和第 180 天的死亡率。结果在这项研究中，58 名（17.0%）患者接受了膀胱切除术，140 名（41.2%）患者接受了前列腺切除术，142 名（41.8%）患者接受了肾肿瘤手术。平均年龄为 74.8 岁。术后第 30 天和第 180 天，分别有 47.6% 和 37.4% 的病例出现 ADL 功能障碍，作为未完全康复的衡量标准。EI 对第 180 天的死亡率（参考队列：85%；验证中心 1：100%；验证中心 2：50%）和第 180 天的 ADL 损伤（参考队列：75.4%；验证中心 1：72.3%；验证中心 2：83.3%）显示出良好的灵敏度。这项多中心外部验证试验的数据证实，EI 是一种准确可靠的工具，可用于识别死亡风险高或术后功能持续受损的患者。

{"title":"Preoperative geriatric assessment to predict functional outcome after major urologic operations: Results from a multicenter study","authors":"","doi":"10.1016/j.ejso.2024.108693","DOIUrl":"10.1016/j.ejso.2024.108693","url":null,"abstract":"<div><h3>Introduction</h3><p>Major urological tumor surgery entails a severe risk of unexpected adverse events, persistent functional deterioration, and death in older patients. The Erlangen Index (EI) geriatric assessment tool has previously been shown to predict incomplete functional recovery following major urological tumor surgery in an elderly patient collective. We prospectively evaluated assessment tools including EI in a multicenter setting.</p></div><div><h3>Materials and methods</h3><p>A total of 340 patients over the age of 65 were assessed prospectively before and after cystectomy, prostatectomy, or renal tumor surgery at three academic centers in Germany and Austria. Endpoints were long-term functional deterioration (Activities of daily living (ADL) measured by Barthel-Index) at day 30 and day 180, and mortality at day 180.</p></div><div><h3>Results</h3><p>In this study 58 (17.0 %) patients underwent cystectomy, 140 (41.2 %) prostatectomy and 142 (41.8 %) a kidney tumor operation. Mean age was 74.8 years. ADL impairment as a measure of incomplete recovery at day 30 and 180 after surgery were recorded in 47.6 % and 37.4 % of cases, respectively. The EI showed good sensitivity for mortality at day 180 (reference cohort: 85 %, validation center 1: 100 %, validation center 2: 50 %) and for ADL impairment at day 180 (reference cohort 75.4 %, validation center 1 72.3 %, validation center 2 83.3 %).</p></div><div><h3>Conclusion</h3><p>Elderly patients with a poor performance status have a high risk of persistent functional deterioration. Data from this multicenter external validation trial confirms the EI as an accurate and reliable tool to identify patients with high risk of mortality or persistent postoperative functional impairment.</p></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0748798324007455/pdfft?md5=9ae8875954be95d773421a4eea3465d3&pid=1-s2.0-S0748798324007455-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142238116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perioperative blood transfusions associated with reduced survival in gastroesophageal cancers – A Swedish population-based study

IF 3.5 2区医学 Q2 ONCOLOGY

Ejso

Pub Date : 2024-09-12 DOI: 10.1016/j.ejso.2024.108690

Background

Blood transfusion has been associated with decreased long-term survival in cancer patients, possibly due to various immunological factors. We aimed to evaluate if perioperative transfusions decrease survival in patients who undergo resection for esophageal or gastric cancer and to identify factors associated with such events.

Methods

A population-based cohort study was conducted based on the Swedish National Registry for Esophageal and Gastric Cancer, which prospectively collects clinical data of patients with these tumors. Almost all patients (96 %) resected for esophageal or gastric cancer in Sweden between 2017 and 2022 were included. Survival data were acquired from the Swedish Cause of Death Registry. Multivariable Cox regression was used to calculate hazard ratios (HR) with 95 % confidence intervals (CI), adjusted for age, fitness, neoadjuvant therapy, surgical access, and pathological TNM stage.

Results

Of all 1365 patients, 227 (17 %) received perioperative transfusions. Transfusion was associated with an increased risk of all-cause mortality within 3 years of surgery (adjusted HR 1.50, 95 % CI 1.17–1.91). To exclude the influence of surgery-related postoperative complications, a sensitivity analysis was performed excluding patients who died within 30 days of resection and the negative impact of transfusions on 3-year mortality remained (adjusted HR 1.30, 95 % CI 1.01–1.68). Increasing age, open surgery, esophagectomy, perioperative bleeding, and nodal tumor involvement were all associated with an increased likelihood of receiving transfusions.

Conclusion

Perioperative blood transfusions might have a negative impact on 3-year survival in patients who undergo surgery for esophageal or gastric cancer.

{"title":"Perioperative blood transfusions associated with reduced survival in gastroesophageal cancers – A Swedish population-based study","authors":"","doi":"10.1016/j.ejso.2024.108690","DOIUrl":"10.1016/j.ejso.2024.108690","url":null,"abstract":"<div><h3>Background</h3><p>Blood transfusion has been associated with decreased long-term survival in cancer patients, possibly due to various immunological factors. We aimed to evaluate if perioperative transfusions decrease survival in patients who undergo resection for esophageal or gastric cancer and to identify factors associated with such events.</p></div><div><h3>Methods</h3><p>A population-based cohort study was conducted based on the Swedish National Registry for Esophageal and Gastric Cancer, which prospectively collects clinical data of patients with these tumors. Almost all patients (96 %) resected for esophageal or gastric cancer in Sweden between 2017 and 2022 were included. Survival data were acquired from the Swedish Cause of Death Registry. Multivariable Cox regression was used to calculate hazard ratios (HR) with 95 % confidence intervals (CI), adjusted for age, fitness, neoadjuvant therapy, surgical access, and pathological TNM stage.</p></div><div><h3>Results</h3><p>Of all 1365 patients, 227 (17 %) received perioperative transfusions. Transfusion was associated with an increased risk of all-cause mortality within 3 years of surgery (adjusted HR 1.50, 95 % CI 1.17–1.91). To exclude the influence of surgery-related postoperative complications, a sensitivity analysis was performed excluding patients who died within 30 days of resection and the negative impact of transfusions on 3-year mortality remained (adjusted HR 1.30, 95 % CI 1.01–1.68). Increasing age, open surgery, esophagectomy, perioperative bleeding, and nodal tumor involvement were all associated with an increased likelihood of receiving transfusions.</p></div><div><h3>Conclusion</h3><p>Perioperative blood transfusions might have a negative impact on 3-year survival in patients who undergo surgery for esophageal or gastric cancer.</p></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S074879832400742X/pdfft?md5=2a252f11a96a04aadcf9bc2cbbb475de&pid=1-s2.0-S074879832400742X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142238255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multidisciplinary team meetings and their impact on survival in rectal cancer. Population-based analysis in Catalonia (Spain)

IF 3.5 2区医学 Q2 ONCOLOGY

Ejso

Pub Date : 2024-09-12 DOI: 10.1016/j.ejso.2024.108675

Background

Multidisciplinary team meetings (MTMs) are considered a pillar of cancer care; however, evidence of the independent benefit of MTMs on survival in rectal cancer is controversial.

Methods

This population-based cohort analysis included patients undergoing surgery for primary rectal cancer with curative intent. We drew data derived from three clinical audits conducted in Catalonia from 2011 to 2020. The primary outcome was 2-year survival. Multivariable Cox regression analysis was used to assess the hazard ratio for death in patients whose cases were versus were not discussed in a preoperative MTM.

Results

A total of 5249 patients were included (66.1 % male, 58.3 % aged 60–79 years, 63.2 % receiving anterior resection): 4096 cases were discussed in a preoperative MTM, and 1153 were not. Multivariable Cox proportional hazards regression analysis showed that the MTM group had better survival than those with no preoperative MTM (hazard ratio 1.22, 95 % confidence interval 1.02–1.48), after adjusting for potential confounders.

Conclusions

Preoperative MTM may be associated with improved survival in patients with rectal cancer in Catalonia. Efforts to ensure universal access to MTMs for all newly diagnosed patients should be supported.

{"title":"Multidisciplinary team meetings and their impact on survival in rectal cancer. Population-based analysis in Catalonia (Spain)","authors":"","doi":"10.1016/j.ejso.2024.108675","DOIUrl":"10.1016/j.ejso.2024.108675","url":null,"abstract":"<div><h3>Background</h3><p>Multidisciplinary team meetings (MTMs) are considered a pillar of cancer care; however, evidence of the independent benefit of MTMs on survival in rectal cancer is controversial.</p></div><div><h3>Methods</h3><p>This population-based cohort analysis included patients undergoing surgery for primary rectal cancer with curative intent. We drew data derived from three clinical audits conducted in Catalonia from 2011 to 2020. The primary outcome was 2-year survival. Multivariable Cox regression analysis was used to assess the hazard ratio for death in patients whose cases were versus were not discussed in a preoperative MTM.</p></div><div><h3>Results</h3><p>A total of 5249 patients were included (66.1 % male, 58.3 % aged 60–79 years, 63.2 % receiving anterior resection): 4096 cases were discussed in a preoperative MTM, and 1153 were not. Multivariable Cox proportional hazards regression analysis showed that the MTM group had better survival than those with no preoperative MTM (hazard ratio 1.22, 95 % confidence interval 1.02–1.48), after adjusting for potential confounders.</p></div><div><h3>Conclusions</h3><p>Preoperative MTM may be associated with improved survival in patients with rectal cancer in Catalonia. Efforts to ensure universal access to MTMs for all newly diagnosed patients should be supported.</p></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142238115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differences in characteristics and outcomes between early-onset colorectal cancer and late-onset colorectal cancers

IF 3.5 2区医学 Q2 ONCOLOGY

Ejso

Pub Date : 2024-09-11 DOI: 10.1016/j.ejso.2024.108687

Introduction

Colorectal cancer (CRC) represents a significant health burden worldwide, with a notable increase in early-onset colorectal cancer (EOCRC) cases, defined as those diagnosed before the age of 50 years.

Materials and methods

Using data from Taiwan's national cancer registry and a retrospective cohort from Chang Gung Memorial Hospital, this study analyzed CRC cases diagnosed between 2008 and 2019. The analysis compared the EOCRC and late-onset CRC (LOCRC) groups in terms of clinicopathological characteristics, pre-diagnostic symptoms, and survival outcomes.

Results

The analysis revealed a continuous increase in the annual incidence of EOCRC, with colon cancer and rectal cancer rising by 3.2 % and 3.3 %, respectively. Patients with EOCRC presented with more aggressive disease characteristics, such as signet-ring cell adenocarcinoma, mucinous adenocarcinoma, and poorly differentiated grade. Advanced stages at diagnosis, stages III and IV, were more common with EOCRC (62.4 %) than with LOCRC (50.3 %). Patients with EOCRC reported rectal bleeding, changes in bowel habits, and abdominal pain more frequently than those in the LOCRC group. There is a strong association between stool-related symptoms and left-sided CRC. Despite similar surgical outcomes, the 5-year cancer-specific survival rate of patients with stage IV EOCRC was significantly lower than that of patients with LOCRC (32.8 % vs. 51.9 %, p = 0.012).

Conclusion

This study highlights a persistent rise in the incidence of EOCRC, with patients presenting with more aggressive disease and experiencing inferior survival. These findings underscore the importance of heightened awareness and early detection strategies for CRC, especially in younger populations, to improve the prognosis.

{"title":"Differences in characteristics and outcomes between early-onset colorectal cancer and late-onset colorectal cancers","authors":"","doi":"10.1016/j.ejso.2024.108687","DOIUrl":"10.1016/j.ejso.2024.108687","url":null,"abstract":"<div><h3>Introduction</h3><p>Colorectal cancer (CRC) represents a significant health burden worldwide, with a notable increase in early-onset colorectal cancer (EOCRC) cases, defined as those diagnosed before the age of 50 years.</p></div><div><h3>Materials and methods</h3><p>Using data from Taiwan's national cancer registry and a retrospective cohort from Chang Gung Memorial Hospital, this study analyzed CRC cases diagnosed between 2008 and 2019. The analysis compared the EOCRC and late-onset CRC (LOCRC) groups in terms of clinicopathological characteristics, pre-diagnostic symptoms, and survival outcomes.</p></div><div><h3>Results</h3><p>The analysis revealed a continuous increase in the annual incidence of EOCRC, with colon cancer and rectal cancer rising by 3.2 % and 3.3 %, respectively. Patients with EOCRC presented with more aggressive disease characteristics, such as signet-ring cell adenocarcinoma, mucinous adenocarcinoma, and poorly differentiated grade. Advanced stages at diagnosis, stages III and IV, were more common with EOCRC (62.4 %) than with LOCRC (50.3 %). Patients with EOCRC reported rectal bleeding, changes in bowel habits, and abdominal pain more frequently than those in the LOCRC group. There is a strong association between stool-related symptoms and left-sided CRC. Despite similar surgical outcomes, the 5-year cancer-specific survival rate of patients with stage IV EOCRC was significantly lower than that of patients with LOCRC (32.8 % vs. 51.9 %, p = 0.012).</p></div><div><h3>Conclusion</h3><p>This study highlights a persistent rise in the incidence of EOCRC, with patients presenting with more aggressive disease and experiencing inferior survival. These findings underscore the importance of heightened awareness and early detection strategies for CRC, especially in younger populations, to improve the prognosis.</p></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S074879832400739X/pdfft?md5=8375ed1bf842aad6160d8fa4874f6d0d&pid=1-s2.0-S074879832400739X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142238114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Progress of intracranial metastases during the interval before stereotactic radiosurgery, a retrospective cohort analysis 立体定向放射外科手术前颅内转移灶进展情况的回顾性队列分析

IF 3.5 2区医学 Q2 ONCOLOGY

Ejso

Pub Date : 2024-09-10 DOI: 10.1016/j.ejso.2024.108676

Introduction

The incidence of intracranial metastatic disease is increasing worldwide. As a valuable treatment modality, stereotactic radiosurgery requires detailed imaging, and this study evaluated the differences between imaging obtained on the day of treatment compared to historical or referral imaging.

Materials and methods

A retrospective cohort study was performed, evaluating all the patients presenting with eligible referral imaging in a 13-month period and comparing this imaging to the imaging taken on the day of treatment. Numbers of additional metastases, volumes and volume differences among the images were compared.

Results

There was a median interval of 19 days between the acquisition of the diagnostic or referral scan and the day of treatment imaging. Even the group that had the shortest interval (up to 2 weeks) showed at least one additional deposit in 50 % of the patients. Volume was increased in 75 % of this group. Longer intervals were associated with higher increases in volume.

Conclusion

These results demonstrate the increase in the disease burden in patients with intracranial metastatic disease, in relation to number and volume, in the interval between the referral and treatment imaging. This has significant implications for planning pathways, to ensure that metastatic deposits are not missed or undertreated.

导言颅内转移性疾病的发病率在全球呈上升趋势。作为一种重要的治疗方式，立体定向放射外科需要详细的成像，本研究评估了治疗当天获得的成像与历史或转诊成像之间的差异。材料和方法进行了一项回顾性队列研究，评估了 13 个月内所有符合转诊成像条件的患者，并将这些成像与治疗当天的成像进行了比较。结果诊断或转诊扫描与治疗当天的成像之间的中位间隔为 19 天。即使是间隔时间最短的一组（最长 2 周），也有 50% 的患者至少多出一个沉积物。在这组患者中，75%的患者血容量增加。这些结果表明，颅内转移性疾病患者的疾病负担在转诊和治疗成像之间的间隔期内，在数量和体积上都有所增加。这对规划治疗路径具有重要意义，可确保转移性沉积物不会被漏诊或治疗不足。

{"title":"Progress of intracranial metastases during the interval before stereotactic radiosurgery, a retrospective cohort analysis","authors":"","doi":"10.1016/j.ejso.2024.108676","DOIUrl":"10.1016/j.ejso.2024.108676","url":null,"abstract":"<div><h3>Introduction</h3><p>The incidence of intracranial metastatic disease is increasing worldwide. As a valuable treatment modality, stereotactic radiosurgery requires detailed imaging, and this study evaluated the differences between imaging obtained on the day of treatment compared to historical or referral imaging.</p></div><div><h3>Materials and methods</h3><p>A retrospective cohort study was performed, evaluating all the patients presenting with eligible referral imaging in a 13-month period and comparing this imaging to the imaging taken on the day of treatment. Numbers of additional metastases, volumes and volume differences among the images were compared.</p></div><div><h3>Results</h3><p>There was a median interval of 19 days between the acquisition of the diagnostic or referral scan and the day of treatment imaging. Even the group that had the shortest interval (up to 2 weeks) showed at least one additional deposit in 50 % of the patients. Volume was increased in 75 % of this group. Longer intervals were associated with higher increases in volume.</p></div><div><h3>Conclusion</h3><p>These results demonstrate the increase in the disease burden in patients with intracranial metastatic disease, in relation to number and volume, in the interval between the referral and treatment imaging. This has significant implications for planning pathways, to ensure that metastatic deposits are not missed or undertreated.</p></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142233728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Ejso

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀